TRAF6 is required for skeletal muscle regeneration.
Salk team develops Drug that prevents, reverses deadly liver damage in mice. Chronic damage to the liver eventually creates a wound that never heals. This condition, called fibrosis, gradually replaces normal liver cells -which detoxify the food and liquid we consume – with more and more scar tissue until the organ no longer works.
Scientists at the Salk Institute have identified a drug that halts this unchecked accumulation of scar tissue in the liver. The small molecule, called JQ1, prevented as well as reversed fibrosis in animals and could help the millions of people worldwide affected by liver fibrosis and cirrhosis, caused by alcoholism and diseases like hepatitis.
“After too much damage in the liver, the scar tissue itself causes more scar tissue,” says Ronald Evans, professor and director of Salk’s Gene Expression Laboratory and a Howard Hughes Medical Institute investigator. When the liver is damaged, small collections of hepatic stellate cells that specialize in storing vitamin A are called upon to tend to the wound. These activated stellate cells shed their vitamin A, travel to the site of injury and create thick, fibrous scar tissue to wall off and repair the damage. However, with prolonged organ stress, healthy liver cells become replaced by scar tissue, eventually leading to organ failure.
“Traditional therapies targeting inflammation don’t work because these cells have multiple ways to bypass the drug,” says Michael Downes, a Salk senior scientist and author of the paper. “In contrast, our strategy was to stop the fibrotic response at the genome level where these pathways converge.” The search for the critical genome pathway uncovered a regulatory protein, BRD4, that is a master regulator of liver fibrosis.
With this new knowledge in hand, the Salk team found JQ1 successfully inhibited BRD4 and halted the transformation of hepatic stellate cells into fiber-producing cells. This is good news, as JQ1 is a prototype of a new class of drugs currently being tested in human clinical trials for various cancers. “Our results indicate that BRD4 is a driver of chronic fibrosis and a promising therapeutic target for treating liver disease,” says Evans, who also holds the March of Dimes Chair in Molecular and Developmental Biology. “We think this discovery may also treat fibrosis in other organs, like the lung, pancreas and kidney.”
http://www.salk.edu/news-release/fighting-liver-fibrosis-the-wound-that-never-heals/
Recent Comments